EP3452077A4 - Compositions and methods of providing thyroid hormone or analogs thereof - Google Patents
Compositions and methods of providing thyroid hormone or analogs thereof Download PDFInfo
- Publication number
- EP3452077A4 EP3452077A4 EP17793078.1A EP17793078A EP3452077A4 EP 3452077 A4 EP3452077 A4 EP 3452077A4 EP 17793078 A EP17793078 A EP 17793078A EP 3452077 A4 EP3452077 A4 EP 3452077A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- analogs
- compositions
- methods
- thyroid hormone
- providing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/046—Thyroid disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662331148P | 2016-05-03 | 2016-05-03 | |
US201662344271P | 2016-06-01 | 2016-06-01 | |
PCT/US2017/030435 WO2017192458A1 (en) | 2016-05-03 | 2017-05-01 | Compositions and methods of providing thyroid hormone or analogs thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3452077A1 EP3452077A1 (en) | 2019-03-13 |
EP3452077A4 true EP3452077A4 (en) | 2020-01-08 |
Family
ID=65238439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17793078.1A Pending EP3452077A4 (en) | 2016-05-03 | 2017-05-01 | Compositions and methods of providing thyroid hormone or analogs thereof |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3452077A4 (en) |
CN (1) | CN109475605A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995020953A1 (en) * | 1994-02-01 | 1995-08-10 | Knoll Ag | Therapeutic agents containing thyroid hormones |
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
WO2006081518A2 (en) * | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
WO2008057464A2 (en) * | 2006-11-01 | 2008-05-15 | King Pharmaceuticals Research And Development, Inc. | Compositions and methods for improving the bioavailability of liothyronine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
-
2017
- 2017-05-01 EP EP17793078.1A patent/EP3452077A4/en active Pending
- 2017-05-01 CN CN201780041419.3A patent/CN109475605A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995020953A1 (en) * | 1994-02-01 | 1995-08-10 | Knoll Ag | Therapeutic agents containing thyroid hormones |
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
WO2006081518A2 (en) * | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
WO2008057464A2 (en) * | 2006-11-01 | 2008-05-15 | King Pharmaceuticals Research And Development, Inc. | Compositions and methods for improving the bioavailability of liothyronine |
Non-Patent Citations (1)
Title |
---|
See also references of WO2017192458A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN109475605A (en) | 2019-03-15 |
EP3452077A1 (en) | 2019-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3298043B8 (en) | Sirp polypeptide compositions and methods of use | |
HK1256726A1 (en) | Carrier-binding agent compositions and methods of making and using the same | |
EP3288958A4 (en) | Compositions of obeticholic acid and methods of use | |
EP3435956A4 (en) | Photo-stabilized compositions and methods of use | |
EP3116511A4 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
ZA202104969B (en) | Compositions comprising 15-hepe and methods of using the same | |
EP3349743A4 (en) | Methods and compositions of inhibiting dcn1-ubc12 interaction | |
HK1254960A1 (en) | Cryoprecipitate compositions and methods of preparation thereof | |
EP3110891A4 (en) | Low-voc compositions and methods of making and using the same | |
HK1251979A1 (en) | Peptide compositions and methods of use | |
EP3402443A4 (en) | Devices and compositions and methods of use thereof | |
HK1250345A1 (en) | Compositions comprising 15-oxo-epa or 15-oxo-dgla and methods of making and using same | |
HK1247136A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
IL249695A0 (en) | Low substituted polymyxins and compositions thereof | |
EP3367998A4 (en) | Novel method of use and compositions | |
EP3496942A4 (en) | Compositions containing gallium and/or indium and methods of forming the same | |
IL262729A (en) | Compositions and methods of providing thyroid hormone or analogs thereof | |
EP3273783A4 (en) | Methods for improvement of visual function and compositions used therein | |
EP3319930A4 (en) | Methods and compositions for the stabilizaton of proteins | |
EP3468569A4 (en) | Glucagon analogs and methods of use thereof | |
EP3270985A4 (en) | Polypeptide compositions and methods of using the same | |
EP3288542A4 (en) | Compositions and methods for administering antibodies | |
EP3256094A4 (en) | Dental compositions and methods of use | |
EP3204120A4 (en) | Methods and compositions for increasing the potency of antifungal agents | |
IL274563A (en) | Methods of using and compositions containing dulaglutide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0038220000 Ipc: A61K0009280000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20191210 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 5/14 20060101ALI20191204BHEP Ipc: A61K 9/28 20060101AFI20191204BHEP Ipc: A61K 31/198 20060101ALI20191204BHEP Ipc: A61K 9/20 20060101ALI20191204BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230120 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SPECTRIX THERAPEUTICS, LLC |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TENGLER, MARK |